Clinical trials: Type1 Diabetes
Diabetes Mellitus, Type 1
Effect of Insulin Glulisine Compared to Insulin Aspart and Insulin Lispro When Administered by Continuous Subcutaneous Insulin Infusion (CSII) on Specific Pump Parameters in Patient With Type 1 Diabetes Mellitus
Primary objective: To demonstrate the superiority of insulin glulisine over insulin aspart and insulin lispro administered by external pump in term of unexplained hyperglycemia and/or infusion set occlusion.
- Trial name
- PUMP (NCT00607087)
- Testing
- Insulin glulisine, Insulin lispro, Insulin aspart
- Where
- 12 sites in United States, Australia and 10 more
- Volunteers
- 289 people
- Sponsor
- Sanofi
Diabetes Mellitus, Type 1
Islet Transplantation in Type 1 Diabetics Using the Edmonton Protocol of Steroid Free Immunosuppression
This trial will study the ability of islet transplantation to restore glycemic control and achieve insulin independence in type 1 diabetic subjects with life-threatening hypoglycemia and unawareness, or recurrent hyperglycemia…
- Trial name
- NCT00133809
- Testing
- Transplantation of Human Islets
- Where
- United States
- Volunteers
- 8 people
- Sponsor
- Emory University
Diabetes Mellitus, Type 1
Control-IQ Technology 2.0 Adult and Adolescent Feasibility Study
The purpose of this study is to obtain preliminary safety and performance data on planned improvements to Control-IQ technology.
- Trial name
- NCT05014789
- Testing
- Control-IQ technology 2.0
- Where
- United States
- Volunteers
- 66 people
- Sponsor
- Tandem Diabetes Care, Inc.
Type1diabetes, Low Carbohydrate Diet
Metabolic Changes Induced by a Very Low Carbohydrate Diet in Youth With Type 1 Diabetes
As more adolescents with type 1 diabetes (T1D) opt to follow very low carbohydrate diets to improve glucose control, it is becoming increasingly important to study the metabolic and neurological changes that occur on these diets…
- Trial name
- NCT04955691
- Testing
- low carbohydrate diet, standard carbohydrate diet
- Where
- United States
- Volunteers
- 19 people
- Sponsor
- Yale University
Type 1 Diabetes
Continuos Subcutaneous Insulin Infusion in Italy
This is an observational, multicenter, cross sectional study, collecting clinical and metabolic informations about patients treated with CSII in Italy.
- Trial name
- IMITA2 (NCT02620917)
- Where
- Italy
- Volunteers
- 6,623 people
- Sponsor
- University of Padova
Diabetes Mellitus, Type 1
Non-compliance on Treatment Among Diabetic Students at Sohag University
A cross-sectional study on diabetic students in Sohag University will be conducted to collect data about factors affecting compliance and adherence to diabetes treatment and its impact on development of complications.
- Trial name
- NCT05286450
- Where
- Egypt
- Volunteers
- 153 people
- Sponsor
- Sohag University
Diabetes, Diabetes Mellitus, Type 1
Effect of Insulin Detemir on Use of Energy in Type 1 Diabetes
This trial is conducted in Europe. The purpose of this trial is to investigate if there is any change in the mechanism of energy expenditure (i.e.
- Trial name
- NCT00509925
- Testing
- insulin detemir, insulin NPH, insulin aspart
- Where
- United Kingdom
- Volunteers
- 23 people
- Sponsor
- Novo Nordisk A/S
Diabetes, Diabetic Foot
Diabetic Foot Ulcer Study Comparing Cytal Wound Matrix 1-Layer to Standard of Care
This is a two-armed randomized controlled trial (RCT) primarily aimed at determining if application of Cytal Wound Matrix 1-Layer intervention to diabetic foot ulcers shows improved wound closure rates when compared to standard…
- Conditions
- Diabetes, Diabetic Foot, Diabetes Mellitus, Type 2, Diabetes Mellitus, Type 1
- Trial name
- NCT03626623
- Testing
- Cytal Wound Matrix 1-Layer, Standard of Care (SOC)
- Where
- 3 sites in United States
- Volunteers
- 15 people
- Sponsor
- Integra LifeSciences Corporation
Type 1 Diabetes
Sensor-Augmented Insulin Delivery: Insulin Plus Glucagon Versus Insulin Alone
This study aims to test an insulin and glucagon delivery algorithm designed to be used in conjunction with a continuous glucose monitoring system.
- Trial name
- NCT00797823
- Testing
- Insulin, Asp(B28)-, Glucagon
- Where
- United States
- Volunteers
- 14 people
- Sponsor
- Legacy Health System
Type 1 Diabetes
Selecting Insulin Analogs for Closed-Loop Control Using Multiplex Pharmacokinetic Profiling
The investigators are doing this research study to compare the pharmacokinetics (PK) (rate of absorption) of insulin lispro (Humalog), insulin aspart (Novolog), and insulin glulisine (Apidra) within individual subjects.
- Trial name
- NCT01684943
- Testing
- Multiplex pharmacokinetic profiling, Continuous insulin monitoring
- Where
- United States
- Volunteers
- 33 people
- Sponsor
- Massachusetts General Hospital
Type 1 Diabetes
Atorvastatin in New Onset Type 1 Diabetes Mellitus (T1DM)
The goal of this application is to evaluate the safety and efficacy of atorvastatin as a potential treatment to preserve beta cell function in children and young adults with newly diagnosed type 1 diabetes (T1DM).
- Trial name
- TIDM (NCT00529191)
- Testing
- Atorvastatin
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- Children's Hospital of Philadelphia
Diabetes Mellitus, Type 1
Research Study to Look at Fast-acting Insulin Aspart With the Insulin Pump System 'iLet™' in Adults With Type 1 Diabetes
The iLet™ is a new insulin pump that is programmed to work with a Continuous Glucose Monitoring (CGM) device. This is to give participants insulin automatically. The CGM device is already available for sale.
- Trial name
- NCT03816761
- Testing
- Fast-acting insulin aspart, iLet™
- Where
- United States
- Volunteers
- 24 people
- Sponsor
- Novo Nordisk A/S
Islet Transplantation, Type1 Diabetes Mellitus
CGM Use in Islet Transplant Recipients
A study assessing glucose variability in subjects with Type 1 Diabetes who have had islet transplant.
- Trial name
- NCT03427931
- Testing
- Continuous Glucose Monitor (CGM)
- Where
- United States
- Volunteers
- 7 people
- Sponsor
- University of Virginia
Diabetes, Diabetes Mellitus, Type 1
A Trial Evaluating Compatibility and Safety of FIAsp and Insulin Aspart With an External Continuous Subcutaneous Insulin Infusion System in Adult Subjects With Type 1 Diabetes
This trial is conducted in Europe and the United States of America (USA). The aim of this trial is to evaluate compatibility and safety of FIAsp (faster-acting insulin aspart) and insulin aspart (NovoRapid®) with an external…
- Trial name
- onset® 4 (NCT01999322)
- Testing
- Faster-acting insulin aspart, insulin aspart
- Where
- 2 sites in United States, Germany
- Volunteers
- 37 people
- Sponsor
- Novo Nordisk A/S
Type 1 Diabetes, Latent Autoimmune Diabetes in Adults
Digital Exercise for Middle-Aged Adults With Type 1 Diabetes and Other Absolute Insulin Deficiency Diabetes
The challenges of living with type 1 diabetes often stand in the way of getting enough exercise. Continuous blood sugar monitoring has revolutionized type 1 diabetes care but remains underutilized to sustainably support exercise…
- Conditions
- Type 1 Diabetes, Latent Autoimmune Diabetes in Adults, Pancreatitis
- Trial name
- NCT06098729
- Testing
- Digital Exercise
- Where
- United States
- Volunteers
- 24 people
- Sponsor
- Yale University
Type 1 Diabetes
Overnight Closed Loop Study in U.S.
This is a multicenter feasibility study. Up to 85 subjects will be enrolled in the study. The goal of the study is to demonstrate that the Hybrid Closed Loop (HCL) System is safe to be used in an even larger study outside of…
- Trial name
- OCL (NCT01857973)
- Testing
- Hybrid Closed Loop
- Where
- 6 sites in United States
- Volunteers
- 78 people
- Sponsor
- Medtronic MiniMed, Inc.
Diabetes Mellitus, Type 1
Efficacy and Safety of Nasal Glucagon for Treatment of Hypoglycemia in Adults
The purpose of this study is to assess the efficacy, pharmacokinetics (PK), pharmacodynamics (PD), and safety of 3 milligrams (mg) glucagon (glucagon nasal powder) administered nasally compared with commercially available…
- Trial name
- NCT01994746
- Testing
- Nasal Glucagon, Intramuscular Glucagon
- Where
- 8 sites in United States
- Volunteers
- 77 people
- Sponsor
- Eli Lilly and Company
Diabetes Mellitus, Type 1, Type 1 Diabetes
Human Versus Analogue Insulin for Youth With Type 1 Diabetes in Low-Resource Settings
The primary objective of this trial is to determine whether insulin glargine reduces the risk of serious hypoglycemia or improves Time in Range at 6 months when compared against standard of care human insulin (e.g.
- Trial name
- HumAn-1 (NCT05614089)
- Testing
- Insulin Glargine, NPH or premixed 70/30 (human insulin)
- Where
- 3 sites in Bangladesh, Tanzania
- Volunteers
- 400 people
- Sponsor
- Jing Luo
Diabetes Mellitus, Type 1, Insulin-dependent Diabetes Mellitus
Phase 2, Randomized, Open-Label, Crossover, PD/PK Study of a Novel Pram-Insulin Co-Formulation in Adults With T1D
This is a randomized, open-label, active-controlled, single-dose, 3-treatment, 3-period, 3-way crossover, comparative PD and PK inpatient study in adults with T1D.
- Trial name
- NCT04074317
- Testing
- PRAM9, Regular Insulin + Pramlintide, Regular Insulin
- Where
- United States
- Volunteers
- 18 people
- Sponsor
- Xeris Pharmaceuticals
Diabetes Mellitus, Type 1
Empagliflozin add-on to Insulin in Type 1 Diabetes Mellitus Over 28 Days
Placebo-controlled, double blind (triple-dummy technique), randomised parallel design comparison of three oral doses (2.5 mg, 10 mg, and 25 mg) of empagliflozin in patients with T1DM as adjunctive therapy to insulin over 28 days.
- Trial name
- NCT01969747
- Testing
- Empagliflozin medium, Empagliflozin low
- Where
- 2 sites in Austria, Germany
- Volunteers
- 75 people
- Sponsor
- Boehringer Ingelheim